Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song
{"title":"熊去氧胆酸治疗对 COVID-19 自身免疫性肝病患者的影响及其临床预后","authors":"Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song","doi":"10.1016/j.bsheal.2024.04.004","DOIUrl":null,"url":null,"abstract":"<div><p>To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (<em>P</em> = 0.003) and immunosuppressant (<em>P</em> = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (<em>P</em> = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (<em>P</em> = 0.018). Logistic regression analysis showed that UDCA use (<em>P</em> = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (<em>P</em> = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (<em>P</em> = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.</p></div>","PeriodicalId":36178,"journal":{"name":"Biosafety and Health","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590053624000545/pdfft?md5=bd6ab21d4a00accdd4ec3b047274df81&pid=1-s2.0-S2590053624000545-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis\",\"authors\":\"Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song\",\"doi\":\"10.1016/j.bsheal.2024.04.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (<em>P</em> = 0.003) and immunosuppressant (<em>P</em> = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (<em>P</em> = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (<em>P</em> = 0.018). Logistic regression analysis showed that UDCA use (<em>P</em> = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (<em>P</em> = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (<em>P</em> = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.</p></div>\",\"PeriodicalId\":36178,\"journal\":{\"name\":\"Biosafety and Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590053624000545/pdfft?md5=bd6ab21d4a00accdd4ec3b047274df81&pid=1-s2.0-S2590053624000545-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biosafety and Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590053624000545\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590053624000545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis
To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (P = 0.003) and immunosuppressant (P = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (P = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (P = 0.018). Logistic regression analysis showed that UDCA use (P = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (P = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (P = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.